What Remmie does

Remmie Inc. is a women-founded digital health company that develops and markets connected otoscopes and a paired AI-powered telehealth platform for ear, nose, and throat assessment, primarily targeting parents of children with recurrent ear infections and healthcare providers delivering telehealth ENT care. The company operates from Washington and California, designing hardware in California and operating sales, customer support, and provider partnerships out of Seattle with extension offices in San Francisco, Los Angeles, Spokane, and London. The product portfolio includes Remmie 4 (FDA-registered USB-connected AI otoscope at $149), Remmie 3 (Wi-Fi enabled otoscope at $149), and Remmie Pro (FDA-registered, CE-marked, Health Canada- and Australian TGA-cleared professional digital otoscope), with a clinician-reviewed subscription service (Remmie Care) and pre-visit assessment platform (Remmie Report). The proprietary Remmie.ai diagnostic engine, a multi-modal deep learning model analyzing eardrum images paired with symptom text, is under NIH SBIR Phase 2-funded development with Lurie Children's Hospital targeting FDA approval as a medical device.

Remmie generates revenue through a hybrid hardware-plus-subscription model: one-time device sales ($149 consumer devices; pro pricing not publicly disclosed) plus recurring Remmie Care subscriptions ($10/month or $25 per submission), Remmie Report basic plan ($12/year), and consumable specula accessories ($10 for 10 pieces, $50 for 50 pieces). Distribution is multi-channel: own DTC e-commerce at remmiehealth.com, Amazon marketplace, four global distributors covering the UK, Australia, and Canada, and direct B2B sales to healthcare providers. Enterprise footprints include 300+ accounts, 20+ clinics, 6 school districts, and 2 US hospital pilots, alongside B2B2C integrations with telehealth partners including Poppins (7 U.S. states), Rocket Doctor, CareClix, MyTelemedicine, PM Pediatrics, QDoc, Kavira, and Nextera. Non-dilutive NIH funding (~$3M SBIR Phase 2) and prior accelerator backing (Techstars, Plug and Play, Sunstone Management) support ongoing R&D.

The company has filed four patent applications protecting Remmie.ai methods and maintains HIPAA-compliant AWS cloud infrastructure with HL7/FHIR EMR integration. Customer-reported outcomes include 67% of users avoiding an in-person doctor's visit, 90% willingness to recommend, $2,032 average cost savings per avoided ER visit, 47 NPS, 80% engagement at 6 months, and a 3.9-star Amazon rating. Reported market context cites $4 billion in annual U.S. healthcare spending on ear infection diagnosis, 16 million annual episodes, and 5 of 6 children experiencing ear infections before age three.

Name

Remmie

Legal name

Remmie Inc.

Website

https://remmiehealth.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Remmie develops FDA-registered connected otoscopes (Remmie 4, 3, Pro) paired with HIPAA-compliant telehealth subscriptions (Remmie Care, Remmie Report) and a NIH-funded AI diagnostic engine (Remmie.ai), serving parents of children with ear infections and clinicians delivering ENT telehealth.

Ownership category

akta.pro rank

Product category

Digital Otoscope Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

ENT (Otolaryngology) Telemedicine Platforms (HLALAGAM)

akta.pro secondary industries

Portable, Mobile & Point-of-Care Imaging Systems (HLAHABAL), Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration) (HLACAPAJ)

Keywords

• Digital otoscope devices
• Telehealth ENT solutions
• AI ear diagnostics
• Home medical imaging
• Pediatric telehealth hardware

Headquarters

HQ city

Culver City

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Hardware Device Sales: Sale of digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) directly to consumers and healthcare providers. One-time hardware purchase with optional subscription services.
2. Remmie Care Subscription: Monthly subscription service ($10/month) providing pre-visit assessment with clinician review, 24-hour turnaround for findings, and ability to email submissions to physicians. Also per-submission option at $25.
3. Remmie Report: Annual subscription plan ($12/year) with 1 review credit annually for basic assessment services.
4. NIH SBIR Grant Funding: Nearly $3 million SBIR Phase 2 grant from NIH NIDCD for development of Remmie.ai diagnostic tool.
5. Enterprise/Provider Contracts: B2B contracts with healthcare organizations, clinics, hospital networks, and school districts for deployment of Remmie Care platform with volume pricing.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

Remmie designs, manufactures and sells FDA-registered digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) that connect to smartphones, tablets and computers to capture ear, nose and throat imagery for at-home examination and telehealth consultations. The hardware is paired with subscription telehealth services (Remmie Care and Remmie Report) that route captured images to clinicians for remote review, and an in-development AI diagnostic engine (Remmie.ai) for automated ENT disease classification.

Product overview

Remmie Health offers a portfolio of FDA-registered digital otoscopes and AI-powered healthcare platforms for at-home ENT care. The product line includes Remmie 4 (USB-connected AI-powered otoscope with highest image quality), Remmie 3 (wireless Wi-Fi enabled intelligent home otoscope with AI guidance), and Remmie Pro (professional-grade digital otoscope for medical providers). These hardware products integrate with the Remmie Report platform and Remmie Care telehealth service for remote clinical assessment. The Remmie.ai AI diagnostic engine is under development for ENT disease classification. Accessories include disposable specula sets. All devices enable patients to capture ear, nose, and throat images and videos for telehealth consultations with clinicians.

Differentiator

Problem solved

Functional benefit

Brands

• Remmie Report: AI-powered ear-nose-throat pre-visit assessment platform enabling patients to capture images and receive clinician review asynchronously.
• Remmie Care
• Remmie.ai

Products and services

• Remmie 4 FDA-registered USB-connected AI-powered otoscope for at-home ear, nose, and throat examinations on phones, tablets, and computers. Features HD720p resolution, 3.7mm diameter lens, USB Type-C connection, IP67 waterproof design, and works in 60 seconds without Wi-Fi. Includes 30-day Remmie Care clinician review trial and is FSA/HSA eligible.
• Remmie 3 Wireless Wi-Fi-enabled intelligent home otoscope with AI-guided image capture for ear, nose, and throat examination. Features HD720p resolution, 3.9mm diameter lens, 5 levels of adjustable brightness, and up to 30 fps video streaming. Compatible with iOS/iPadOS 14+ and Android 10+. FSA/HSA eligible at $149 per device.
• Remmie Pro FDA-registered digital otoscope designed for medical professionals, clinics and telemedicine providers. Features a 2 megapixel sensor (1920x1080), Wi-Fi connectivity, snapshot functionality, and store-and-forward capability for saving and sharing images and videos to EMR systems.
• Remmie Care Telehealth service connecting users with board-certified clinicians for ENT consultation. Offers a BYOD (bring your own device) subscription at $10/month, per-submission fee at $25, and integrates with platforms including CareClix ($50 cash visit), MyTelemedicine ($29.95/month subscription) and PM Pediatrics (telehealth in 15 states). Delivers 24-hour clinician turnaround for feedback on submissions.
• Remmie Report AI-powered ENT pre-visit assessment platform with a patient app and clinical portal. Patients capture ear, nose, and throat images and share health information; clinicians review remotely to guide patients to the right care. Basic consumer plan at $12/year includes one annual review credit; provider subscription includes 3 months of Remmie Care service and generates summary reports that can be sent via PDF email for upload to patient portals such as MyChart.
• Specula Set Disposable specula (ear tips) for Remmie otoscopes. Soft-touch thermoplastic elastomer rubber (85° shore hardness) protects the ear canal. Available in packs of 10 ($10) or 50 ($50). 3.7mm diameter compatible with all Remmie otoscope models.

Quantifiable outcome

• 67% of customers avoided an in-person doctor's visit
• +5 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability8 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• PoppinscoreGTM or Marketing Partner · 4 March 2026Poppins partnered with Remmie Health to offer at-home telehealth solution for pediatric ear infections. Parents use Remmie's digital otoscope to capture video of child's eardrum and share with Poppins clinicians for remote diagnosis and prescription. Service marketed as concierge pediatric offering eliminating office visits. Available in 7 U.S. states: CT, FL, IL, NJ, NY, PA, TX. Plans starting at $29/month or $249/year.
• Lurie Children's HospitalcoreStrategic or Co-development Partner · 14 June 2024Clinical research partnership for Remmie.ai development involving Chicago's Lurie Children's Hospital. Project aims to improve ENT diagnosis accuracy and reduce healthcare costs, progressing towards FDA approval as a medical device.
• Rocket DoctorminorGTM or Marketing PartnerTelehealth platform partner offering ENT consultations with Remmie integration. Listed as partner on website.
• KaviraminorGTM or Marketing PartnerHealthcare partner listed on company website partnerships section.
• NexteraminorGTM or Marketing PartnerHealthcare partner listed on company website partnerships section.
• QDocminorGTM or Marketing PartnerHealthcare partner listed on company website partnerships section.
• CareClixminorGTM or Marketing PartnerTelehealth platform connecting Remmie users with board-certified clinicians for video consultations. Cash payment $50 per visit or subscription available.
• MyTelemedicineminorGTM or Marketing PartnerTelehealth platform partner with $29.95/month subscription service for Remmie users seeking medical consultations.
• PM PediatricsminorGTM or Marketing PartnerPediatric urgent care provider offering telehealth services to Remmie users in 15 states, 8am-12am daily.
• Hint EcosystemminorGTM or Marketing PartnerDirect primary care ecosystem partner with Dr. Brad Brown testimonial praising Remmie for reducing unnecessary office visits.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Eko Health: Eko Health builds AI-powered digital stethoscopes with FDA-cleared cardiac AI and telehealth integration. Comparable hardware + AI diagnostic + telehealth platform model applied to a different body system (heart vs. ear), making it a relevant category analog for Remmie.ai's diagnostic ambitions.
• Anytime Pediatrics: Anytime Pediatrics is a pediatric telehealth platform offering on-demand virtual care to children, founded by Remmie Clinical Advisor Mick Connors. Comparable in serving pediatric telehealth demand that drives demand for Remmie devices, and represents the software platform side of the combined offering.

Direct peers

• Firefly Global: Firefly Global manufactures digital video otoscopes and dermatoscopes used by medical professionals and for telehealth deployments. Closest direct competitor to Remmie Pro with similar professional-grade imaging specs, EMR integration, and telehealth-oriented positioning.
• Bebird: Bebird is the dominant consumer-priced smart otoscope brand, selling Wi-Fi connected ear scopes on Amazon at $30-60 with companion smartphone apps. Directly comparable product form factor and target consumer use case, though with no AI diagnostic or telehealth integration and at a fraction of Remmie's price point.
• ScopeAround: ScopeAround sells Wi-Fi and USB digital otoscopes for both consumer and medical professional use, with smartphone apps for image/video capture. Directly competes in the same hardware category, with overlapping SKU structure (consumer vs. pro) and similar Amazon DTC distribution.
• TytoCare: TytoCare is the most direct peer — a telehealth platform built around a connected home examination device (Tyto) that enables remote auscultation, otoscopy, and throat imaging for clinicians. Both companies combine FDA-cleared hardware with a clinician review subscription and sell into telehealth partners, health systems, and school programs.
• CellScope (ResMed): CellScope pioneered the smartphone otoscope (Oto Home) for at-home ear exams and telehealth, and was acquired by ResMed. Conceptually identical model to Remmie — consumer otoscope device paired with asynchronous clinician review — and represents the strategic exit benchmark for the category.

Others

• Caregility: Caregility provides enterprise telehealth infrastructure for hospital systems, including virtual care platforms and clinical workflow tools. Adjacent to Remmie's enterprise go-to-market motion targeting health systems and could be a partnership or integration point rather than a direct competitor.

Broad incumbents

• Withings: Withings is an established consumer connected-health device company (smart scales, blood pressure monitors, sleep) sold through retail and DTC channels. Comparable hardware-led D2C model targeting health-conscious households, though without Remmie's specialty ENT/telehealth focus.
• Welch Allyn (Hillrom / Baxter): Welch Allyn is the incumbent leader in professional otoscopes and is now part of Baxter (via Hillrom). Provides the established clinical-grade otoscope baseline that telehealth solutions like Remmie Pro must integrate with or differentiate against in hospital and clinic settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xfacebook.com/remmiehealth
• YouTubeyoutube.com/channel/UCsgH9yV6IXuLJOKfWR3ilWw
• Facebookfacebook.com/remmiehealth
• LinkedInlinkedin.com/company/remmie-health
• Instagraminstagram.com/remmie_health
• TikToktiktok.com/@remmie_health

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remmie